M1 Kliniken AG/€M12
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About M1 Kliniken AG
M1 Kliniken AG, headquartered in Berlin, Germany, specializes in aesthetic medicine and plastic surgery services. Operating under the "M1 Med Beauty" brand, the company offers treatments such as breast augmentation, eyelid lifts, liposuction, and non-invasive procedures like hyaluronic acid and botulinum toxin injections. As of 2023, M1 Kliniken operates 58 specialist centers across ten countries, including Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. The company also manages the M1 Schlossklinik in Berlin, a facility with six operating theaters and 35 beds. M1 Kliniken's strategic focus on specialization and centralized purchasing enables it to offer high-quality medical services at competitive prices.
- Ticker
- €M12
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 280
- Headquarters
- Berlin, Germany
- Website
- www.m1-kliniken.de
M1 Kliniken AG Metrics
BasicAdvanced
€361M
18.00
€1.08
1.01
€1.20
6.15%
Price and volume
Market cap
€361M
Beta
1.01
52-week high
€21.95
52-week low
€13.74
Average daily volume
2.2K
Dividend rate
€1.20
Financial strength
Current ratio
5.479
Quick ratio
3.259
Long term debt to equity
0.018
Total debt to equity
0.039
Dividend payout ratio (TTM)
46.02%
Interest coverage (TTM)
32.89%
Profitability
EBITDA (TTM)
32.574
Gross margin (TTM)
20.09%
Net profit margin (TTM)
7.86%
Operating margin (TTM)
12.38%
Effective tax rate (TTM)
31.04%
Revenue per employee (TTM)
€920,000
Management effectiveness
Return on assets (TTM)
10.46%
Return on equity (TTM)
15.29%
Valuation
Price to earnings (TTM)
18.003
Price to revenue (TTM)
1.415
Price to book
2.91
Price to tangible book (TTM)
6.14
Price to free cash flow (TTM)
13.354
Free cash flow yield (TTM)
7.49%
Free cash flow per share (TTM)
1.46
Dividend yield (TTM)
6.15%
Forward dividend yield
6.15%
Growth
Revenue change (TTM)
-27.50%
Earnings per share change (TTM)
12.58%
3-year revenue growth (CAGR)
-4.71%
10-year revenue growth (CAGR)
19.52%
3-year earnings per share growth (CAGR)
46.68%
10-year earnings per share growth (CAGR)
5.22%
10-year dividend per share growth (CAGR)
14.87%
Bulls say / Bears say
Beauty revenue rose 11% in H1 2026, while EBIT grew 23.8% and the margin reached 32.7%. That strong profit growth suggests efficiency gains are lifting returns faster than sales. (M1 Kliniken AG)
Demand for aesthetic procedures is expanding: Börsen-Zeitung reported that procedures worldwide rose nearly 4% in 2024 and in Germany nearly 18%. M1’s 59 clinics across ten countries give it a platform to capture some of that demand as it expands. (Börsen-Zeitung)
The sale of the pharmaceutical wholesaler leaves M1 more focused on its higher-margin clinic business. Even after the disposal, H1 adjusted group EBIT rose 9.5% to €19.7m, while Beauty EBIT increased 23.8%. (M1 Kliniken AG)
The €200m lower end of M1’s 2029 Beauty revenue target requires roughly 18% average annual growth from 2025, yet Beauty sales rose only 5.7% in Q1 2026. The company also gives no quantified full-year forecast, making near-term delivery harder to assess. (finanzen.net)
Despite growth in Beauty, H1 reported group EBIT fell to €15.6m from €18.0m and earnings per share to €0.52 from €0.63; the remaining trading segment also recorded a €3m EBIT loss. The disposal makes comparisons difficult and leaves some uncertainty about how quickly the focused group can translate clinic growth into reported earnings. (M1 Kliniken AG)
A sharp prior share-price rise could leave the stock exposed if expansion disappoints: Börsen-Zeitung reported that M1 shares had gained more than 147% over three years by May 2026. That run-up raises the risk that investors already expect strong execution. (Börsen-Zeitung)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
M1 Kliniken AG Financial Performance
Revenues and expenses
M1 Kliniken AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.